Agenus Inc. Stock News

Q1 2020 Agenus Inc Earnings Call

From $30 CPM to $80 and more, it highly depends

Spotlight on European startups

Wireless sensors used to prevent life-saving medicines from spoiling in transit

The general secretaries of the Bharatiya Pratiraksha Mazdoor Sangh, All India Defence Employees' Federation and the Indian National Defence Workers' Federation has issued a joint letter to Defence Min

The FDA clears Agenus' (AGEN) IND application for allogeneic iNKT therapy, agenT-797, which is being developed to treat cancer as well as the deadly COVID-19 pandemic.

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and infections, announced today that it will present data on

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and infectious diseases, announced today the FDA acceptance

Agenus (AGEN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Agenus (AGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

Thank you for standing-by and welcome to Agenus' First Quarter 2020 Conference Call. Dr. Buell, please go ahead. Before we start, we'd like to remind you that this call will include forward-looking

Some publishers are eliminating ad units, while others are repurposing impressions to donate for advertisers’ PSA campaigns or to promote their subscription products.

Cotchett, Pitre & McCarthy, LLP filed a class action lawsuit on behalf of Guy Saperstein, a UC Berkeley Law graduate, against Thomas P. Gohagan &a